Mitglied werden

Johnson & Johnson (JNJ)

Healthcare • Drug Manufacturers - General

49
Beobachten
$230,75
Kurs
+1,54%
Veränderung
555,94 Mrd. $
Marktkapitalisierung
18,75
KGV

Neumann-Score Aktienanalyse

49
von 100 Punkten
Beobachten
Bewertung??/100
Profitabilität??/100
Wachstum??/100

Score-Details freischalten

Werden Sie Mitglied und erhalten Sie Zugang zu allen Analysen.

Mitglied werden

Über Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care product ...

CEO
Joaquin Duato
Mitarbeiter
138.100
Land
US